Menu
Migraine is the third most common illness in the world. One in seven people are affected at some point in their lives. Those who suffer from chronic migraines – that is, having at least fifteen headache days per month, of which eight consist of migraines – often have to limit their lives and take medications with severe side effects. Normally, you cannot work during a migraine attack, which results in large costs to society in the form of both medical care and loss of production. Our Ozilia® Migraine method is expected to preventively decrease the number of headache days, which is what the current study intends to prove.
Jan-Åke Åkesson is a neurologist and meets patients suffering from chronic migraine on a daily basis. Jan-Åke was among the trial doctors who took part in a previous clinical study that was carried out in Sweden. Jan-Åke considers Ozilia® Migraine. a great possibility to treat patients who don’t experience any effects of existing treatments.
“It would mean that yet another group of patients would be able to get preventative treatment. When the new CGRP antagonist drugs came out on the market, many believed that the problem had been solved, and that ‘this is something that will help everyone’. But that’s not the case. There is a great number of patients who don’t experience any effects of it. Ozilia® Migraine. is therefore a very interesting treatment method alternative, consisting of a totally different treatment mechanism, for the patients who don’t experience any effects of existing treaments.”
“It’s a bit complicated to say how many doses are needed, or the length and frequency of the treatment. Botox treatment involves 20-30 injections every three months. While many feel it’s a convenient treatment compared to having to take pills every day, others feel uneasy about the number of injections they have to get. This treatment is pretty intense when it is carried out, but it’s not needed every day. I also feel it can help those who experience sinus and nose problems in between migraine attacks.”
“It doesn’t really hurt, but patients can experience discomfort, due to a reaction that causes itching in the nose and the eyes may tear up a little bit. But I can’t remember meeting a patient who wants to abstain from treatment because of it.”
For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.
For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.
To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH).
The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.